160 related articles for article (PubMed ID: 36160145)
1. Biologics for psoriasis patients under 18 years of age: Real-world evidence from the Chinese psoriasis real world evidence research group.
Zheng YX; Ye LR; Yan BX; Chen SQ; Cai SQ; Man XY
Front Med (Lausanne); 2022; 9():1009991. PubMed ID: 36160145
[TBL] [Abstract][Full Text] [Related]
2. Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review.
Blauvelt A; Burge R; Malatestinic W; Brnabic A; Guo J; Janardhanan M; Zhu B
J Manag Care Spec Pharm; 2021 Jan; 27(1):84-94. PubMed ID: 33377444
[No Abstract] [Full Text] [Related]
3. Efficacy, Safety, and Pharmacoeconomic Analysis of Adalimumab and Secukinumab for Moderate-to-Severe Plaque Psoriasis: A Single-Center, Real-World Study.
Li G; Gu Y; Zou Q; Wang Y; Xiao Y; Xia D; Zhan T; Zhou X; Wang Q; Yan W; Li W
Dermatol Ther (Heidelb); 2022 Sep; 12(9):2105-2115. PubMed ID: 35953612
[TBL] [Abstract][Full Text] [Related]
4. Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study.
Li Y; Lu JJ; Zhong XY; Yu YY; Yu N; Wang Y; Yi XM; Ding YF; Shi YL
Clin Cosmet Investig Dermatol; 2022; 15():2245-2252. PubMed ID: 36304759
[TBL] [Abstract][Full Text] [Related]
5. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
6. Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry.
Lockshin B; Harrison RW; McLean RR; Crabtree MM; Konicek BW; Zhu B; Malatestinic WN; Atiya B; Murage MJ; Burge RT
Dermatol Ther (Heidelb); 2022 Dec; 12(12):2797-2815. PubMed ID: 36331713
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate-to-severe psoriasis after 1 year of treatment: Real-world practice.
Herrera-Acosta E; Garriga-Martina GG; Suárez-Pérez JA; Martínez-García EA; Herrera-Ceballos E
Dermatol Ther; 2020 May; 33(3):e13313. PubMed ID: 32181962
[TBL] [Abstract][Full Text] [Related]
8. Dose escalation and associated costs in biologic treatment of psoriasis based on real-world data.
Bagel J; Glick B; Wu JJ; Chopra I; Song X; Brouillette M; Mendelsohn A; Rozzo S; Han G
J Med Econ; 2021; 24(1):782-791. PubMed ID: 34107834
[TBL] [Abstract][Full Text] [Related]
9. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
Bokor-Billmann T; Schäkel K
J Dermatolog Treat; 2019 May; 30(3):216-220. PubMed ID: 30051725
[TBL] [Abstract][Full Text] [Related]
10. Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study.
Colombo D; Bianchi L; Fabbrocini G; Corrao S; Offidani A; Stingeni L; Costanzo A; Pellacani G; Peris K; Bardazzi F; Argenziano G; Ruffolo S; Dapavo P; Carrera C; Fargnoli MC; Parodi A; Romanelli M; Malagoli P; Talamonti M; Megna M; Raspanti M; Paolinelli M; Hansel K; Narcisi A; Conti A; De Simone C; Chessa MA; De Rosa A; Provenzano E; Ortoncelli M; Moltrasio C; Fidanza R; Burlando M; Tonini A; Gaiani FM; Simoni L; Ori A; Fiocchi M; Zagni E
Dermatol Ther; 2022 Jan; 35(1):e15166. PubMed ID: 34676662
[TBL] [Abstract][Full Text] [Related]
11. Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response.
Rompoti N; Sidiropoulou P; Panagakis P; Stratigos A; Papoutsaki M; Stefanaki E; Vavouli C; Politou M; Befon A; Kostakis P; Rigopoulos D; Nicolaidou E
J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1240-1247. PubMed ID: 31953892
[TBL] [Abstract][Full Text] [Related]
12. A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents.
Bronckers IMGJ; Paller AS; West DP; Lara-Corrales I; Tollefson MM; Tom WL; Hogeling M; Belazarian L; Zachariae C; Mahé E; Siegfried E; Blume-Peytavi U; Szalai Z; Vleugels RA; Holland K; Murphy R; Puig L; Cordoro KM; Lambert J; Alexopoulos A; Mrowietz U; Kievit W; Seyger MMB;
JAMA Dermatol; 2020 Apr; 156(4):384-392. PubMed ID: 32022846
[TBL] [Abstract][Full Text] [Related]
13. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
Al Sawah S; Foster SA; Burge R; Amato D; Schacht A; Zhu B; Hartz S; Leonardi C
J Med Econ; 2017 Dec; 20(12):1224-1230. PubMed ID: 28760056
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis).
Valenti M; Gargiulo L; Ibba L; Malagoli P; Amoruso F; Balato A; Bardazzi F; Burlando M; Carrera CG; Dapavo P; Dini V; Gaiani FM; Girolomoni G; Guarneri C; Lasagni C; Loconsole F; Marzano AV; Maurelli M; Megna M; Orsini D; Travaglini M; Costanzo A; Narcisi A
Dermatol Ther (Heidelb); 2024 Jun; 14(6):1649-1657. PubMed ID: 38748344
[TBL] [Abstract][Full Text] [Related]
15. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.
Warren RB; Gooderham M; Burge R; Zhu B; Amato D; Liu KH; Shrom D; Guo J; Brnabic A; Blauvelt A
J Am Acad Dermatol; 2020 May; 82(5):1138-1149. PubMed ID: 31884091
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA.
Fitzgerald T; Zhdanava M; Pilon D; Shah A; Hilts A; Lefebvre P; Feldman SR
Dermatol Ther (Heidelb); 2023 Apr; 13(4):1053-1068. PubMed ID: 36929120
[TBL] [Abstract][Full Text] [Related]
17. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
[TBL] [Abstract][Full Text] [Related]
18. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
Blauvelt A; Leonardi C; Elewski B; Crowley JJ; Guenther LC; Gooderham M; Langley RG; Vender R; Pinter A; Griffiths CEM; Tada Y; Elmaraghy H; Lima RG; Gallo G; Renda L; Burge R; Park SY; Zhu B; Papp K;
Br J Dermatol; 2021 Jun; 184(6):1047-1058. PubMed ID: 32880909
[TBL] [Abstract][Full Text] [Related]
19. Understanding efficacy-safety balance of biologics in moderate-to-severe pediatric psoriasis.
Golhen K; Winskill C; Theiler M; Buettcher M; Yeh YH; Zhang N; Welzel T; Pfister M
Front Med (Lausanne); 2022; 9():944208. PubMed ID: 36226155
[TBL] [Abstract][Full Text] [Related]
20. Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study.
Chiricozzi A; Burlando M; Caldarola G; Conti A; Damiani G; De Simone C; Dini V; Malagoli P; Peccerillo F; Potenza C; Scala E; Skroza N; Balato A
Am J Clin Dermatol; 2020 Jun; 21(3):441-447. PubMed ID: 31786732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]